TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

This trial is testing an experimental drug called TAK-243 in patients with acute myeloid leukemia (AML — a fast-growing blood cancer) or myelodysplastic syndromes with increased abnormal cells (MDS-IB), whose cancer has come back or has not responded to previous treatments. **You may be eligible if...** - You have been diagnosed with AML or MDS with increased abnormal bone marrow cells - Your cancer has relapsed (come back) or is refractory (has not responded) to at least one prior treatment - For AML: you have tried at least two rounds of intensive chemotherapy, or at least two cycles of a gentler treatment regimen - For MDS: you have tried at least one prior treatment **You may NOT be eligible if...** - Your cancer has not been confirmed by a specialist laboratory - You have not yet tried any prior treatment - Your overall health or organ function is too poor to safely receive this drug Talk to your doctor to see if this trial is right for you.